FDA Approval for Corneal Crosslinking in Keratoconus
“The US Food and Drug Administration (FDA) has approved a riboflavin ophthalmic solution (Photrexa, Avedro) that treats a corneal disease called progressive keratoconus with corneal collagen crosslinking, the manufacturer announced today.
The approval extends to a version of the riboflavin ophthalmic solution that contains dextran (Photrexa Viscous) and an electronic device (KXL System) that irradiates the solutions with ultraviolet A light after they have been applied to the cornea.
Keratoconus is a degenerative disease that causes progressive thinning and distortion of the cornea. The condition can result in myopia, astigmatism, and even blindness. Corneal collagen crosslinking aims to halt the progress of keratoconus by strengthening chemical bonds in the cornea. Successful crosslinking can avert the need for a corneal implant.”